Logo
Rejuran S Lidocaine 1 x 1 ml

Rejuran S Lidocaine 1 x 1 ml

Rejuran

Skin booster
  • Approved for medical use by the Korean Ministry of Food and Drug Safety (MFDS) for scar treatment indications.
  • Approved by the Singapore Health Sciences Authority (HSA) for medical use as a PN scar Treatment injectable.
  • Described by multiple distributors and clinics as a CE Certified dermal tissue stimulator / scar Regeneration injectable based on purified polynucleotides.
  • Manufactured by PharmaResearch Co., Ltd. in South Korea under medical Device quality Management systems for PN Based injectables.
Polynucleotide injectable for acne scars and depressed scars

Description

Rejuran S Lidocaine 1 x 1 ml is a specialised injectable from the Rejuran family, formulated specifically for the treatment of acne scars and other depressed scars. It contains long-chain polynucleotides (PN) derived from salmon DNA, which have a high water-binding capacity and viscoelasticity suitable for rebuilding and improving the appearance of scarred skin. Rejuran S (Scar) has the highest polynucleotide concentration among Rejuran injectables, providing a dense, highly viscous gel that acts both as a regenerative dermal stimulator and a scar-filling scaffold. The PN molecules stimulate fibroblasts, promote collagen synthesis, support wound repair and collagen remodelling, and exert anti-inflammatory effects. This lidocaine-containing presentation is intended to increase patient comfort during intradermal injection. Rejuran S is approved for medical use by the Korean MFDS and Singapore HSA and is designed for professional treatment of atrophic acne scars, sunken scars and uneven texture.

Bnefits

  • Highly concentrated polynucleotide formulation specifically designed for atrophic acne scars and depressed scars.
  • Accelerates skin healing and cell regeneration by providing a structural scaffold for dermal repair.
  • Stimulates fibroblasts and collagen production, promoting collagen remodelling and skin thickening.
  • Reduces the visibility and depth of acne scars, boxcar scars and other sunken scars.
  • Improves overall skin quality and texture in scarred areas, including smoothness and resilience.
  • High water-binding capacity and viscoelasticity help plump depressed areas and support dermal structure.
  • Anti-inflammatory properties support calmer, healthier skin in treated regions.
  • Contains lidocaine to improve injection comfort compared with non-anaesthetised PN formulations.
  • Can be combined with fractional lasers, radiofrequency or other resurfacing treatments as part of a comprehensive scar-management protocol.

Indications

  • Atrophic acne scars (e.g. boxcar and rolling scars).
  • Sunken or depressed scars from trauma or surgery.
  • General dermal defects with loss of volume and contour due to scarring.
  • Uneven skin texture and localised surface irregularities related to scars.
  • Adjunctive therapy alongside resurfacing procedures (e.g. CO2 laser, fractional RF) for acne scars, as determined by the treating physician.

Composition

  • Polynucleotide (PN, polydeoxyribonucleotide sodium) high concentration (commonly 2% / ~20 mg/ml) derived from salmon DNA, providing the highest PN load among Rejuran injectables.
  • Local anaesthetic (numbing agent) 0.3% (typically lidocaine hydrochloride) to reduce injection discomfort.
  • Buffered aqueous solution (e.g. phosphate buffer with sodium phosphate/disodium phosphate, water for injections; exact excipients may vary by market labelling).
  • Some distributor listings also mention the presence of hyaluronic acid in certain Rejuran S scar-regeneration formulations; the core mechanism, however, is driven by the high PN content.

Formulation

  • High-viscosity, transparent PN-based injectable gel designed for pinpoint treatment of scars.
  • PN concentration around 2% with high viscoelasticity, giving strong localised support and filling effect within depressed scars.
  • Acts as a dermal tissue stimulator and structural scaffold, rather than a traditional volumising filler.
  • Contains a small amount of lidocaine (0.3%) for increased patient comfort.
  • Sterile, pyrogen-controlled, non-cross-linked PN solution supplied in a pre-filled syringe.
  • Intended for intradermal injection directly at the base of scars by qualified healthcare professionals.

Packaging

  • Box containing 1 pre-filled 1 ml syringe of Rejuran S Lidocaine.
  • Typically used with a thin 30G needle (e.g. 30G × 8 mm JBP nano needle) for precise intradermal scar injections.
  • Syringe and needle supplied in sterile blister packaging (needle supply may vary by distributor).
  • Outer carton bearing product identification, batch number and expiry date.
  • Instructions for use (IFU) / product leaflet and, where applicable, traceability labels for patient records.

Usage

  • For professional use only: Rejuran S must be administered by a licensed doctor or cosmetologist trained in aesthetic medicine and injectable scar treatments.
  • Perform a detailed clinical evaluation of scar type, depth and location; review medical history and contraindications; obtain informed consent prior to treatment.
  • Cleanse the treatment area thoroughly and apply an appropriate topical anaesthetic cream; allow sufficient time for anaesthesia to take effect, then remove and disinfect with antiseptic.
  • Inject small amounts of Rejuran S intradermally at the base of each scar using a fine needle (commonly 30G), employing serial puncture or micro-droplet technique.
  • Place micro-deposits directly under and within each atrophic scar to create a three-dimensional PN scaffold and induce collagen formation and dermal remodelling.
  • Treat only healthy skin; avoid injecting into infected or inflamed areas.
  • Typical treatment protocol: an initial course of 3–4 sessions at intervals of about 4–6 weeks, adjusting number of sessions and dosing based on clinical response and scar severity.
  • Rejuran S may be combined with fractional resurfacing lasers or radiofrequency (e.g. CO2, fractional RF) as part of a combined approach to depressed acne scars; sequencing and intervals should follow clinic protocol and physician judgment.
  • Inject slowly with low, controlled pressure; aspirate cautiously where appropriate to help avoid intravascular injection; maintain correct intradermal depth and avoid bolus injections into vessels.
  • After injection, gentle massage may be applied around the treated scars, if clinically appropriate, to distribute the product evenly.
  • Advise patients to avoid makeup on treated areas for several hours and to avoid intense exercise, saunas, hot baths, sunbeds and direct sun exposure for at least 24 hours or as directed by clinic protocol.
  • Instruct patients on basic post-treatment care, including the possible use of topical antibiotic preparations when prescribed to help prevent infection.
  • Always follow the official instructions for use (IFU) supplied with the product and comply with local professional and regulatory guidelines.

Contraindications

  • Known hypersensitivity or allergy to polynucleotides, salmon-derived products, lidocaine or other amide-type local anaesthetics, or any component of the formulation.
  • History of severe allergic reactions or anaphylaxis to injectable medical or aesthetic products.
  • Active skin infection, inflammation, or dermatologic disease (bacterial, viral such as herpes simplex, or fungal) at or near the intended injection sites.
  • Autoimmune diseases or immunocompromised conditions unless, after careful individual evaluation, the treating physician judges that potential benefits outweigh risks.
  • Uncontrolled systemic illnesses or acute febrile conditions.
  • Bleeding disorders, significant coagulation abnormalities or concurrent use of anticoagulant or high-dose antiplatelet therapy that increases bleeding risk, unless carefully assessed and managed by a physician.
  • Pregnancy and breastfeeding (generally not recommended due to insufficient safety data).
  • Patients under 18 years of age.
  • Presence of permanent fillers or other foreign bodies in the same area where interaction risk exists, unless evaluated and approved by an experienced practitioner.
  • Any general contraindication to injectable aesthetic procedures or local anaesthetics as determined by the treating healthcare professional.

Adverse Effects

  • Common, usually mild and transient injection-site reactions such as redness (erythema), mild swelling or oedema, tenderness, itching, or a feeling of tightness.
  • Injection-site pain or discomfort, generally reduced but not completely eliminated by the presence of lidocaine; typically resolves within hours to a few days.
  • Small papules or bumps at injection points, especially with micro-droplet intradermal technique; these usually subside over several days as the product integrates.
  • Minor bruising or haematoma at injection sites.
  • Temporary skin sensitivity, mild irritation or pruritus in treated areas.
  • Short-term surface irregularities or asymmetry, which may require further assessment, massage or additional treatment.
  • Rare delayed inflammatory or hypersensitivity reactions, such as prolonged erythema, swelling, induration or itching, requiring medical evaluation and potential treatment.
  • Infection at injection sites if aseptic technique is not strictly observed.
  • Very rare but serious complications associated with injectable procedures, including inadvertent intravascular injection leading to tissue ischaemia or necrosis; such events require immediate emergency management by an appropriately trained physician.
  • Any unexpected, persistent or severe adverse reaction should be promptly assessed and managed according to clinical best practice and the product’s official guidance.

Storage Conditions

  • Store according to manufacturer’s labelling, typically in a cool, dry place away from direct sunlight (commonly in the 2–25 °C range; check packaging for exact requirements).
  • Do not freeze.
  • Keep the syringe in its original packaging until use to protect from light and contamination.
  • Avoid exposure to excessive heat or sudden temperature changes.
  • Do not use after the expiry date printed on the packaging.
  • Use only if the syringe, blister and outer packaging are intact and the solution appears clear and free from visible particles.
  • Single-use sterile device: do not resterilise and do not reuse any opened or partially used syringe.

Duration

Clinical improvements in scar depth, texture and dermal quality typically build over a series of 3\u20134 sessions spaced 4\u20136 weeks apart. Results are commonly maintained for around 9\u201312 months or longer after a completed treatment course, depending on scar severity, individual healing response, adjunctive procedures and lifestyle. Maintenance or top-up sessions may be performed at the clinician\u2019s discretion to sustain results.

Onset

Initial plumping and softening of depressed scars may be visible within days to a few weeks after the first session due to local PN scaffold and hydration, while more pronounced improvements in scar depth, texture and dermal structure develop gradually over 4\u20138 weeks as fibroblasts produce new collagen and tissue remodelling occurs, with further gains after each subsequent session.

Browse more Skin booster

Top Treatments

Top Cities in the UK